Novartis CEO sees no need for big takeover
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/2/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Bristol-Myers Squibb (BMY) Granted European Commission Approval Opdivo (Nivolumab)
June 2, 2017 5:06 PM EDTBristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Todays decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for... More
Bristol-Myers Squibb (BMY) & Seattle Genetics (SGEN) Announce Expanded Collaboration to Evaluate Combination of Opdivo (Nivolumab) & ADCETRIS (Brentuximab Vedotin) in Phase 3 Clinical Trial
June 2, 2017 6:03 AM EDTBristol-Myers Squibb Company (NYSE: BMY) and Seattle Genetics, Inc. (Nasdaq:... More
